Which trial do we need? Highly bioavailable oral β-lactams versus quinolones or trimethoprim-sulfamethoxazole for gram-negative bacteraemia

Steven Y.C. Tong*, Dafna Yahav, Nick Daneman

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)1110-1113
Number of pages4
JournalClinical Microbiology and Infection
Issue number9
StatePublished - Sep 2023

Cite this